Cao Richard Y, Li Qing, Miao Yi, Zhang Ying, Yuan Wenchao, Fan Li, Liu Gongliang, Mi Qiongyao, Yang Jian
Laboratory of Immunology, Shanghai Xuhui Central Hospital/Shanghai Zhongshan-Xuhui Hospital, Fudan University/Shanghai Clinical Research Center, Chinese Academy of Sciences, 966 Middle Huaihai Road, Shanghai 200031, China.
Department of Rehabilitation, Shanghai Xuhui Central Hospital/Shanghai Zhongshan-Xuhui Hospital, Fudan University/Shanghai Clinical Research Center, Chinese Academy of Sciences, 966 Middle Huaihai Road, Shanghai 200031, China.
Biomed Res Int. 2016;2016:9869208. doi: 10.1155/2016/9869208. Epub 2016 Nov 27.
MicroRNAs have been demonstrated to be involved in human diseases, including cardiovascular diseases. Growing evidences suggest that microRNA-155, a typical multifunctional microRNA, plays a crucial role in hematopoietic lineage differentiation, immunity, inflammation, viral infections, and vascular remodeling, which is linked to cardiovascular diseases such as coronary artery disease, abdominal aortic aneurysm, heart failure, and diabetic heart disease. The effects of microRNA-155 in different cell types through different target genes result in different mechanisms in diseases. MicroRNA-155 has been intensively studied in atherosclerosis and coronary artery disease. Contradictory results of microRNA-155 either promoting or preventing the pathophysiological process of atherosclerosis illustrate the complexity of this pleiotropic molecule. Therefore, more comprehensive studies of the underlying mechanisms of microRNA-155 involvement in cardiovascular diseases are required. Furthermore, a recent clinical trial of Miravirsen targeting microRNA-122 sheds light on exploiting microRNA-155 as a novel target to develop effective therapeutic strategies for cardiovascular diseases in the near future.
微小RNA已被证明与包括心血管疾病在内的人类疾病有关。越来越多的证据表明，典型的多功能微小RNA——微小RNA-155，在造血谱系分化、免疫、炎症、病毒感染和血管重塑中起关键作用，而这些都与冠状动脉疾病、腹主动脉瘤、心力衰竭和糖尿病性心脏病等心血管疾病相关。微小RNA-155通过不同的靶基因在不同细胞类型中产生的作用，导致了疾病中不同的机制。微小RNA-155已在动脉粥样硬化和冠状动脉疾病中得到深入研究。微小RNA-155促进或阻止动脉粥样硬化病理生理过程的矛盾结果，说明了这种多效性分子的复杂性。因此，需要对微小RNA-155参与心血管疾病的潜在机制进行更全面的研究。此外，最近一项针对微小RNA-122的Miravirsen临床试验，为在不久的将来将微小RNA-155开发为心血管疾病有效治疗策略的新靶点提供了线索。
